

Attorney Docket No. 46963-DIV (71417)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT	Isner, et al.	EXAMINER:	Gambel, Phillip
U.S.S.N.:	09/228,020	GROUP:	1644
FILED:	January 11, 1999	Conf. No.	7379
FOR:	METHODS FOR REGULATING ANGIOGENESIS		

Commissioner for Patents,
Washington, DC 20231

OFFICIAL

Phillip Gambel

*****12/5/02

CERTIFICATE OF FACSIMILE

I hereby certify that this Transmittal is being sent via facsimile on **December 5, 2002** addressed to the:
Commissioner for Patents, Washington, DC 20231, Attn: Phillip Gambel at fax no. (703) 746-5293.


Helen Tarbi

TRANSMITTAL

Enclosed herewith for filing in the subject application are the following:

1. Associate Power of Attorney; and
2. Supplemental Amendment and Remarks.

Applicants believe that no fee is due; however, if for any reason a fee is necessary, you are hereby
authorized and requested to charge Deposit Account No. 04-1105.

Respectfully submitted,

Date: December 5, 2002



Dianne M. Rees, Ph.D.
(Reg. No. 45,281)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

Telephone: 617-951-3351
Customer No. 21874
UOS2 320430.1

E

Attorney Docket No. 46963-DIV (71417)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


APPLICANT Isner, et al. EXAMINER: Gambel, Phillip 21/E
U.S.S.N.: 09/228,020 GROUP: 1644
FILED: January 11, 1999 Conf. No. 7379
FOR: METHODS FOR REGULATING ANGIOGENESIS

Commissioner for Patents
Washington, DC 20231

OFFICIALPhillip Gambel
12/5/02

CERTIFICATE OF FACSIMILE

I hereby certify that this Supplemental Amendment and Remarks is being sent via facsimile on **December 5, 2002** addressed to the: Commissioner for Patents, Washington, DC 20231, Attn: Phillip Gambel at fax no. (703) 746-5293.



Helen Tarbi

SUPPLEMENTAL AMENDMENT AND REMARKS

This paper is responsive to a telephonic interview with the Examiner on December 4, 2002. The Examiner suggested amendments to claim 27 and to the Title and Abstract that would put the case in better condition for allowance.

Accordingly, please amend the subject application as follows.

In the Specification

Please change the title of the Invention, from "Methods For Regulating Angiogenesis" to

E1  Pharmaceutical Products Comprising Endothelial Cell Precursors 

E